Lineage Cell Therapeutics (LCTX) Tops Q1 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $391 thousand versus the consensus estimate of $350 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period
• Thor Industries (THO) Misses Q4 EPS by 13c